ProfileGDS5678 / 1425598_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 91% 90% 92% 91% 91% 91% 92% 90% 89% 91% 90% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1205690
GSM967853U87-EV human glioblastoma xenograft - Control 27.3946591
GSM967854U87-EV human glioblastoma xenograft - Control 37.1806290
GSM967855U87-EV human glioblastoma xenograft - Control 47.7528692
GSM967856U87-EV human glioblastoma xenograft - Control 57.5184791
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1655191
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.1584191
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.5857392
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1128890
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1016389
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2758691
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1905790
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9466689
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0547289